John P. Shannon's Insider Trades & SAST Disclosures
John P. Shannon's most recent trade in Xeris Biopharma Holdings Inc was a trade of 800,000 Common Stock done . Disclosure was reported to the exchange on Jan. 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John P. Shannon.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 800,000 | 2,687,118 (9%) | 2% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 600,000 | 600,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 110,750 | 1,997,868 (7%) | 0% | 3.6 | 394,270 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 110,750 | 1,887,118 (6%) | 0% | 3.6 | 394,270 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 39,443 | 2,108,618 (7%) | 0% | 3.6 | 142,389 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2022 | 300,000 | 300,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2022 | 250,000 | 2,419,612 (8%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.46 per share. | 29 Jan 2022 | 110,750 | 2,148,061 (7%) | 0% | 2.5 | 272,445 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 29 Jan 2022 | 41,334 | 2,355,089 (8%) | 0% | 1.1 | 46,294 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.24 per share. | 29 Jan 2022 | 40,834 | 2,280,961 (8%) | 0% | 2.2 | 91,468 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 29 Jan 2022 | 23,414 | 2,331,675 (8%) | 0% | 1.3 | 29,502 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 29 Jan 2022 | 22,150 | 2,258,811 (8%) | 0% | 2.7 | 58,919 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.11 per share. | 29 Jan 2022 | 15,692 | 2,403,920 (8%) | 0% | 2.1 | 33,110 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 29 Jan 2022 | 9,880 | 2,321,795 (8%) | 0% | 1.2 | 12,251 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.11 per share. | 29 Jan 2022 | 7,497 | 2,396,423 (8%) | 0% | 2.1 | 15,819 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges